Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
AVBP
#2111
ArriVent BioPharma, Inc. Common Stock
22.9
7
+0.22%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
Jahresspanne
Tagesänderung
+0.22%
Monatliche Änderung
-1.20%
6 month change
+19.57%
Jahresänderung
-4.01%
Vorheriger Schlusskurs
22.9
2
Open
22.9
3
Bid
Ask
Low
22.9
3
High
22.9
7
Volumen
76
Märkte
Aktien
Gesundheitswesen
AVBP
Open full chart
Financials
Overview
Finanzbericht
Statistics
Dividends
Quarterly
Annual
Value
2024
TTM
Key stats
Total common shares outstanding
34.02 M
—
Valuation ratios
Enterprise value
831.9 M
2.83 B
Price to earnings ratio
-10.41
-25.11
Price to sales ratio
—
—
Price to cash flow ratio
11.94
27.39
Price to book ratio
3.25
5.23
Enterprise value to EBITDA ratio
—
—
Profitability ratios
Return on assets %
0.29
0.6
Return on equity %
0.31
0.64
Return on invested capital %
962.92
—
Gross margin %
—
—
Operating margin %
—
—
EBITDA margin %
—
—
Net margin %
—
—
Liquidity ratios
Quick ratio
—
—
Current ratio
13.14
55.12
Inventory turnover
—
—
Asset turnover
—
—
Solvency ratios
Debt to assets ratio
—
—
Debt to equity ratio
—
—
Long term debt to total assets ratio
—
—
Long term debt to total equity ratio
—
—
Per share metrics
Operating cash flow per share
2.23
4.12
EBIT per share
—
—
EBITDA per share
—
—
Total debt per share
—
—
Cash per share
6.95
21.45
Net current asset value per share
7.21
27.5
Tangible book value per share
8.19
28.58
Working capital per share
6.66
25.5
Book value per share
8.19
28.58
Nachrichten
Cantor Fitzgerald bestätigt "Overweight"-Rating für ArriVent
ArriVent stock rating reiterated as Overweight by Cantor Fitzgerald
ArriVent BioPharma: Oppenheimer bestätigt "Outperform"-Rating und Kursziel von 44 US-Dollar
Oppenheimer reiterates Outperform rating on ArriVent BioPharma stock
ArriVent BioPharma (AVBP): Its Leading Asset, Furmonertinib, Supports A Cautious Buy
ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts (NASDAQ:AVBP)
Cantor Fitzgerald startet Coverage für ArriVent BioPharma mit "Overweight"-Rating
Cantor Fitzgerald initiates ArriVent BioPharma stock with Overweight rating
ArriVent doses first patient in pivotal phase 3 trial for lung cancer drug
ArriVent BioPharma: BTIG startet mit Kaufempfehlung wegen Onkologie-Potenzial
ArriVent BioPharma stock initiated with Buy rating at BTIG on oncology potential
ArriVent BioPharma stock initiated with Buy rating at Truist on lung cancer drug